Lung-on-minilab is designed as a tool for personalized healthcarewill contribute in precision medicine. Here, the tumor microenvironment was reconstituted using liquid dielectrophoresisarranged as lung tissue. The size of pattern can be customized as stages of cancer. Additionally, this chip was equipped a gradient microfluidic channel which enabled testing combination of medications. This is the first device where chemotherapyimmunotherapy medications can be tested together. This will improve the screening timeserve as an alternative for patients in therapeutic try.

R3CE (Rapid, Reproducible, Rare Cell 3D Expansion) is a clinically validated platform capable of generating single cell-derived organoids within one to four weeks. It outperforms currently 3D culture technologies in terms of yields, time to form organoids,easiness of operation. It also demonstrates similar yieldscost structure to 2D culture protocols. R3CE is ready for drug testing for all clinical samplesprovides sufficient quantity of genomic samples derived from cancer patients. It would help conduct clinical cancer treatment in the translational study.